Spectranetics Submits 510(k) Application for In-Stent Restenosis in the Legs

Spectranetics Corporation announced that it has filed a 510(k) application with the Food and Drug Administration seeking clearance for the treatment of in-stent restenosis in the legs with its commercially available peripheral atherectomy products.
TradingMarkets